| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,620 | 1 | 100 |
| Shrem Itschak | director | 0 | $0 | 1 | $4,620 | $-4,620 |
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership …
Over the last 12 months, insiders at SciSparc Ltd. have bought $0 and sold $4,620 worth of SciSparc Ltd. stock.
On average, over the past 5 years, insiders at SciSparc Ltd. have bought $0 and sold $4,620 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-06-01 | Sale | Shrem Itschak | director | 462 0.7543% | $10.00 | $4,620 | -50.42% |
| Increased Positions | 5 | +100% | 5,782 | +668.44% |
| Decreased Positions | 2 | -40% | 263 | -30.4% |
| New Positions | 4 | New | 3,529 | New |
| Sold Out Positions | 2 | Sold Out | 263 | Sold Out |
| Total Postitions | 8 | +60% | 6,384 | +638.03% |